Home Recalls D-1513-2019
Class II · Moderate risk Terminated Initiated Jul 16, 2019 (7 years ago)
Temozolomide Capsules, 250 mg, 5-count bottle, Rx only, Manufactured by: Deva Holding…
Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.
Why it was recalled
CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.
What was recalled
Temozolomide Capsules, 250 mg, 5-count bottle, Rx only, Manufactured by: Deva Holding A.S., 1 Merkez Mahallesi, Istanbul, Turkey 34303, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-542-07.
Recalling firm Deva Holding AS - Cerkezkoy Subesi
NDC code 67877-542-07
Origin N/A, Turkey
Initiated by Voluntary: Firm initiated
FDA recall number D-1513-2019
What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.
Class II · Moderate risk Ongoing Mar 3, 2026
Reason Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing
Class II · Moderate risk Terminated Jul 16, 2019
Reason CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.
Class II · Moderate risk Terminated Jul 16, 2019
Reason CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.
Class II · Moderate risk Terminated Jul 16, 2019
Reason CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.
Class II · Moderate risk Terminated Jul 16, 2019
Reason CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.